The journal’s Editorial Office and Editorial Board are jointly issuing a resolution and removal of the Journal Notice linked to this article [1]. Following concerns raised about the integrity of the peer-review (misconduct by one of two reviewers), the Editorial Office has conducted a post-publication peer-review of this article. This process included the recruitment of a new independent reviewer and was supervised by the original Academic Editor to ensure full compliance with MDPI’s Editorial Process (
As a result of this process, the Academic Editor and the authors have agreed to update the following aspect(s) of this publication:
Reviewer report 2 has been removed from the peer-review record, while one new review report has been added and uploaded to the peer-review record (
With this update, the Academic Editor is satisfied that the editorial process related to this article has been completed as per MDPI’s Editorial Process policy. The Editorial Office would like to thank the authors for their collaboration during this process.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Reference
1. Titmuss, E.; Milne, K.; Jones, M.R.; Ng, T.; Topham, J.T.; Brown, S.D.; Schaeffer, D.F.; Kalloger, S.; Wilson, D.; Corbett, R.D. et al. Immune Activation Following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. Int. J. Mol. Sci.; 2023; 24, 5869. [DOI: https://dx.doi.org/10.3390/ijms24065869] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36982943]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details



1 Canada’s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC V5Z 4S6, Canada
2 Deeley Research Centre, BC Cancer, Victoria, BC V8R 6V5, Canada
3 Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada
4 Pancreas Centre BC, Vancouver, BC V5Z 1G1, Canada
5 Department of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada
6 Canada’s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC V5Z 4S6, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z2, Canada
7 Deeley Research Centre, BC Cancer, Victoria, BC V8R 6V5, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z2, Canada